A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors

Kwok K. Wong, Paula M. Fracasso, Ronald M. Bukowski, Thomas J. Lynch, Pamela N. Munster, Geoffreyl Shapiro, Pasi A. Jälnne, Joseph P. Eder, Michael J. Naughton, Matthew J. Ellis, Suzanne F. Jones, Tarek Mekhail, Charles Zacharchuk, Jennifer Vermette, Richat Abbas, Susan Quinn, Christine Powell, Howarda Burris

Research output: Contribution to journalArticlepeer-review

241 Scopus citations

Fingerprint

Dive into the research topics of 'A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors'. Together they form a unique fingerprint.

Medicine & Life Sciences